study Champakadi Agada versus Cetirizine in Sheetapitta

Evaluation of comparative efficacy of Champakadi Agada versus Cetirizine in Sheetapitta (Recurrent Urticaria)-A reverse pharmacology approach. - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095267

Enrollment

120

Registered

2025-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18-60 years 2. Patients diagnosed with Sheetapitta (recurrent Urticaria) as per Ayurvedic diagnostic criteria 3. Patients with mild to moderate Sheetapitta (Urticaria) 4. Patients with a history of Sheetapitta (Urticaria) for at least 6 weeks 5. Patients of Sheetapitta willing to give consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. Patients with severe Sheetapitta (Urticaria) requiring hospitalization or emergency treatment 3. Patients taking medications that may interact with Champakadi Agad or Cetrizine, such as antihistamines, corticosteroids, or immunosuppressants 4. Patients with known allergies to Champakadi Agada ingredients or Cetrizine 5. Patients with chronic diseases such as diabetes, hypertension, or kidney disease

Design outcomes

Primary

Measure	Time frame
1. Champakadi Agada will demonstrate significant improvement in reducing Urticaria Activity Score (UAS), reduction in urticarial signs and symptoms compared to Cetrizine at the end of the 6-week treatment period. 2. The optimal dose of Champakadi Agada will be determined, with maximum efficacy at a specific dose and minimal adverse effects. Timepoint: 4-5 weeks, followup will be taken on 14 weeks, 30 weeks, 45th day of enrollment	—

Measure

Time frame

1. Champakadi Agada will demonstrate significant improvement in reducing Urticaria Activity Score (UAS), reduction in urticarial signs and symptoms compared to Cetrizine at the end of the 6-week treatment period. 2. The optimal dose of Champakadi Agada will be determined, with maximum efficacy at a specific dose and minimal adverse effects. Timepoint: 4-5 weeks, followup will be taken on 14 weeks, 30 weeks, 45th day of enrollment

—

Secondary

Measure	Time frame
1. Champakadi Agad may show faster & more significant relief from symptoms such as itching, redness, & swelling compared to Cetrizine. 2. Champakadi Agada may found to be safe & well-tolerated, with fewer adverse effects compared to Cetrizine. 3. In future studies we will be able to find out the phytochemical analysis of Champakadi Agada which revealed the presence of bioactive compounds with anti-inflammatory & anti-allergic properties. 4. The study will be helpful to demonstrate Champakadi Agadas anti-urticarial effects through inhibition of histamine release, reduction of inflammatory cytokines, & modulation of the immune system. Timepoint: 4 weeks	—

Measure

Time frame

1. Champakadi Agad may show faster & more significant relief from symptoms such as itching, redness, & swelling compared to Cetrizine. 2. Champakadi Agada may found to be safe & well-tolerated, with fewer adverse effects compared to Cetrizine. 3. In future studies we will be able to find out the phytochemical analysis of Champakadi Agada which revealed the presence of bioactive compounds with anti-inflammatory & anti-allergic properties. 4. The study will be helpful to demonstrate Champakadi Agadas anti-urticarial effects through inhibition of histamine release, reduction of inflammatory cytokines, & modulation of the immune system. Timepoint: 4 weeks

—

Countries

India

Contacts

Public ContactPRIYA RAUT

Datta meghe ayurvedic medical college hospital and research centre wanadongri Hingana Nagpur.

priyakakde85@gmail.com07972557960

Outcome results